A conflict within the American Diabetes Association has escalated into a wider debate on transparency, editorial independence, and the future of diabetes research, amid a rapidly advancing field and calls for more open debate and collaboration.
The backlash over the American Diabetes Association’s 86th Scientific Sessions has now grown into an organised boycott effort, with patients, advocates, researchers and clinicians circulating separate petitions for people with diabetes and for ADA members and health-care professionals. The dispute, which first erupted in New Orleans in June, has become less about a single conference incident than about who gets to shape diabetes science, how openly disagreement can be aired and whether professional societies can still claim to protect editorial independence.
According to Ars Technica, the controversy began when several prominent diabetes researchers and physicians were removed after distributing copies of an editorial in Diabetes Care that criticised federal actions affecting science and medical research. Those removed included Steven Kahn, Desmond Schatz, Aaron Kelly, Justin Ryder, Irl Hirsch and Maureen Gannon. The ADA later apologised for the way the episode was handled, but tensions deepened after the journal’s deputy editors tried to publish an editorial and seven related opinion pieces about what happened, only for the ADA to refuse them, Ars Technica reported.
The dispute has since broadened into a debate over governance and transparency. The researchers involved have alleged that ADA leadership knew in advance the editorial would be shared and that security and police involvement had been arranged beforehand, claims that remain contested. Through the Zenodo repository, the authors made their collection of articles public after saying they could not be published in Diabetes Care as intended. Their central argument is that the ADA should stay focused on its stated mission to prevent and cure diabetes and improve the lives of people affected by it, rather than becoming a stage for internal conflict.
The fallout has landed at an awkward moment for a field that is trying to balance scientific urgency with public trust. At the same time that the ADA fight was unfolding, Stanford Medicine was describing a different front in type 1 diabetes research: a tolerance-induction strategy that aims to reduce or avoid lifelong immunosuppression after islet-cell transplantation. Stanford said its first patient treated under the protocol achieved more than 90% time in range and an estimated 80% cut in insulin needs, an early signal that cell replacement could one day be more practical if immune rejection can be controlled.
Other recent diabetes research underscores how quickly the field is moving. Endpoints News reported that Sernova Biotherapeutics and Seraxis have agreed to merge into BetaNova Biotherapeutics, combining stem cell-derived islet work with an implantable device designed to help transplanted cells survive and function. Diabetes Care also published a Perspective arguing that people with type 1 diabetes should not be permanently shut out from the cardiorenal benefits of SGLT inhibitors simply because of diabetic ketoacidosis risk, but should instead be studied through a careful, safety-first research pathway.
For many in the diabetes community, that mix of progress and conflict is exactly why the ADA episode has resonated so strongly. The question is not just how the organisation handled one conference confrontation, but whether the broader system can support robust debate, protect researchers and still push ahead on the therapies, technologies and biological insights that people with type 1 diabetes are waiting for.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
